OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 Jun 2024 06:30:31 By Nasdaq GlobeNewswire

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 May 2024 08:36:49 By Nasdaq GlobeNewswire

Ocugen to Present at BIO International Convention 2024

29 May 2024 07:15:00 By Nasdaq GlobeNewswire

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 May 2024 07:02:39 By Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 May 2024 07:00:52 By Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 May 2024 06:30:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 May 2024 08:00:25 By Nasdaq GlobeNewswire

Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 May 2024 16:05:06 By Nasdaq GlobeNewswire

Ocugen to Present at May 2024 Investor Conferences

10 May 2024 07:45:07 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 May 2024 07:30:05 By Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 May 2024 07:15:46 By Nasdaq GlobeNewswire

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 Apr 2024 06:45:00 By Nasdaq GlobeNewswire

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 Apr 2024 09:05:24 By Nasdaq GlobeNewswire

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 Apr 2024 06:30:40 By Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 Apr 2024 07:13:05 By Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 Apr 2024 07:30:34 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 Apr 2024 07:02:26 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 Apr 2024 06:30:43 By Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 Apr 2024 07:02:21 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 Apr 2024 08:00:39 By Nasdaq GlobeNewswire